{"id":604659,"date":"2024-06-03T07:43:56","date_gmt":"2024-06-03T11:43:56","guid":{"rendered":"https:\/\/platohealth.ai\/deciphera-pharmaceuticals-announces-oral-presentation-of-results-from-motion-pivotal-phase-3-study-of-vimseltinib-in-patients-with-tenosynovial-giant-cell-tumor-tgct-at-the-2024-asco-annual-meeting\/"},"modified":"2024-06-03T11:13:41","modified_gmt":"2024-06-03T15:13:41","slug":"deciphera-pharmaceuticals-announces-oral-presentation-of-results-from-motion-pivotal-phase-3-study-of-vimseltinib-in-patients-with-tenosynovial-giant-cell-tumor-tgct-at-the-2024-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/deciphera-pharmaceuticals-announces-oral-presentation-of-results-from-motion-pivotal-phase-3-study-of-vimseltinib-in-patients-with-tenosynovial-giant-cell-tumor-tgct-at-the-2024-asco-annual-meeting\/","title":{"rendered":"Deciphera Pharmaceuticals Announces Oral Presentation Of Results From MOTION Pivotal Phase 3 Study Of Vimseltinib In Patients With Tenosynovial Giant Cell Tumor (TGCT) At The 2024 ASCO Annual Meeting And Online Publication In The Lancet – Medical Device News Magazine","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
Deciphera Pharmaceuticals, Inc.<\/a> (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company\u2019s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, and have been published in The Lancet.<\/em><\/p>\n The article titled \u201cVimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a randomised phase 3 trial\u201d is now available online<\/a> and will be published in a future print issue of The Lancet<\/em>.<\/p>\n \u201cThe results from the MOTION pivotal Phase 3 study provide compelling evidence that vimseltinib can address the unmet medical need in TGCT for an effective and well-tolerated therapy without cholestatic hepatotoxicity,\u201d said Hans Gelderblom, M.D., Ph.D., Chair of the Department of Medical Oncology at Leiden University Medical Center and senior author of the manuscript. \u201cIn addition to its robust antitumor activity and tolerability, vimseltinib also demonstrated clinically significant functional and symptomatic improvements in key quality-of-life measures, which can provide long-term, meaningful benefits to TGCT patients.\u201d<\/p>\n \u201cBuilding upon the strong efficacy results disclosed previously at topline, we are excited to share details on the statistically significant and clinically meaningful improvements that vimseltinib offered TGCT patients across all six key secondary endpoints, along with its favorable safety profile,\u201d said Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera. \u201cWe remain on track to submit an NDA for vimseltinib in the second quarter of 2024, and an MAA in the third quarter of 2024, and look forward to bringing this important new therapy to TGCT patients globally.\u201d<\/p>\n In addition to the results from the MOTION pivotal Phase 3 study, the Company will also be presenting a trial-in-progress poster for the ongoing Phase 1\/2 study of DCC-3116 in combination with ripretinib at the 2024 ASCO Annual Meeting.<\/p>\n Both presentations are available on the Company\u2019s website at www.deciphera.com\/presentations-publications<\/a>. Presentation details are as follows:<\/p>\n Abstract Number:<\/strong> 11500 <\/strong><\/p>\n Abstract Number:<\/strong> TPS11587 DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company’s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":604662,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[52],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/604659"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=604659"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/604659\/revisions"}],"predecessor-version":[{"id":604661,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/604659\/revisions\/604661"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/604662"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=604659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=604659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=604659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Title:<\/strong> Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.
Presenter:<\/strong> William D. Tap, M.D., FASCO, Memorial Sloan Kettering Cancer Center
Presentation Date:<\/strong> Monday, June 3, 2024
Presentation Time:<\/strong> 3:00 \u2013 3:12 PM CT
Key Highlights:<\/strong><\/p>\n\n
\n
\n
\n
\n
Title:<\/strong> DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1\/2 study.
Presenter:<\/strong> Sreenivasa Chandana, M.D., Ph.D., START Midwest, The Cancer & Hematology Centers
Session Date:<\/strong> Saturday, June 1, 2024
Session Time:<\/strong> 1:30 \u2013 4:30 PM CT
Key Highlights:<\/strong><\/p>\n\n
\n
\n